132 related articles for article (PubMed ID: 2129409)
1. Renal transplantation at the Washington Hospital Center: experience with OKT3 and Minnesota antilymphoblast globulin for induction of immunosuppression.
Jonsson J; Light JA; Korb SM
Clin Transpl; 1990; ():275-88. PubMed ID: 2129409
[TBL] [Abstract][Full Text] [Related]
2. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
Light JA; Khawand N; Aquino A; Ali A; Korb S
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
[TBL] [Abstract][Full Text] [Related]
3. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Minnesota antilymphocyte globulin and OKT3 for induction of immunosuppression in renal transplant patients.
Light JA; Khawand N; Ali A; Brems W; Aquino A
Transplant Proc; 1989 Feb; 21(1 Pt 2):1738-40. PubMed ID: 2652569
[TBL] [Abstract][Full Text] [Related]
5. Effective induction immunosuppression for cadaver renal transplantation at the St. Francis Regional Medical Center.
Shield CF
Clin Transpl; 1990; ():265-74. PubMed ID: 2129408
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
8. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation.
Knechtle SJ; Pirsch JD; Groshek M; Reed A; D'Alessandro AM; Kalayoglu M; Belzer FO; Sollinger HW
Transplant Proc; 1991 Feb; 23(1 Pt 2):1581-2. PubMed ID: 1846478
[No Abstract] [Full Text] [Related]
9. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
10. The effect of induction ALG (MALG) on the outcome of steroid-resistant rejection treated with OKT3 in renal transplant patients.
Chiu A; Landsberg D; Cameron EC; Manson AD; Shackleton C
Transplant Proc; 1991 Feb; 23(1 Pt 2):1039-40. PubMed ID: 1899146
[No Abstract] [Full Text] [Related]
11. Prophylactic OKT3 used as induction therapy for heart transplantation.
Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE
Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
[TBL] [Abstract][Full Text] [Related]
12. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
Woodle ES; Bruce DS; Josephson M; Cronin D; Newell KA; Millis JM; Piper JB; O'Laughlin R; Thistlethwaite JR
Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
14. Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3).
Prieto C; Rodriguez-Paternina E; Andrés A; Morales JM; Farias J; Montoyo C; Regueiro JR; Rodicio JL
Transplant Proc; 1990 Aug; 22(4):1753-4. PubMed ID: 2117798
[No Abstract] [Full Text] [Related]
15. OKT3 in severe early rejection: predictors for reversal in renal transplant recipients.
Sumrani N; Delaney V; Rajpoot D; Tejani A; Butt K; Hong J
Transplant Proc; 1990 Aug; 22(4):1750-2. PubMed ID: 2117797
[No Abstract] [Full Text] [Related]
16. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
[TBL] [Abstract][Full Text] [Related]
17. Treatment with OKT3 and cyclosporine for acute allograft rejection.
Schulak JA; Mayes JT; Hricik DE
Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
[TBL] [Abstract][Full Text] [Related]
18. Preliminary results of a prospectively randomized trial of ALG vs OKT3 for steroid-resistant rejection after renal transplantation in the early postoperative period.
Hesse UJ; Wienand P; Baldamus C; Arns W
Transplant Proc; 1990 Oct; 22(5):2273-4. PubMed ID: 2120814
[No Abstract] [Full Text] [Related]
19. Uses of orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation.
Kahana L; Ackermann J; Lefor W; Weinstein S; Wright C; DeQuesada A; Alveranga D; Baxter J; Shires D
Transplant Proc; 1990 Aug; 22(4):1755-8. PubMed ID: 2117799
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
Kormos RL; Herlan DB; Armitage JM; Stein K; Kaufman C; Zeevi A; Duquesnoy R; Hardesty RL; Griffith BP
J Heart Transplant; 1990; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
